btlines

BCX GPW sWIG80 Periodic report · PAP Biznes

Bioceltix SA (BCX) · H1 2026 results

Share price: 68.30 zł · 2026-11-10

Results H1 2026 vs H1 2025 · year over year · published 23 Sep 2026 and 30 Sep 2025

Net loss widened year on year. The language turned more cautious.

Only a basic analysis is available for this company at the moment.

1 · Numbers

Loss widened

Net income vs H1 2025

Net income -10.8M vs -7.5M

Why Net income fell because of the scale of research, development, regulatory, and investment activities characteristic of the company's pre-commercial stage.

2 · How the report reads

More cautious

Language tone vs last period

Report language: restrained for a company report — more cautious than in H1 2025.

Weak signal: formal report language, not a call.

3 · What stood out

In group IVP, one SAE involving a left thigh injury in patient PC02 was recorded, but the link to the treatment was considered unlikely.

Official channels

The company's own website and social media accounts.

Read between the lines

  1. Dropped

    One SAE involving a left thigh injury in patient PC02 was recorded in the IVP group, but the link to the treatment was considered unlikely.

    Source quote
    “In group IVP, one SAE (patient PC02 with a wound/injury to the left thigh) was recorded, for which the link to treatment was considered unlikely.”

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: H1 2026. Ring: H1 2025.

Report language Restrained (was typical)

Restrained for a company report — more cautious than in H1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Full figures

PLN · PAP Biznes report (2026-09-23)

Metric H1 2026 H1 2025 Change
Revenue 0 0
Operating income -10.8M -7.5M Loss widened
Net income -10.8M -7.5M Loss widened
EPS -1.94 -1.53 Loss widened
P/E 12-mo loss 12-mo loss —

Topics

Topics are drawn from the full report text, not management commentary.

Most discussed now

  • 59 (KRS 0000744521), for the period from January 1, 2026, to June 30, 2026
  • From January 1 of the year to June 30, 2026, showing a net loss in the amount of 10,751,110.41 PLN, c.

Faded since H1 2025

  • Dropped Subject of the agreement Single product license, group Right to distribute single products for one route of administration, species…
  • Dropped No merger of companies occurred during the period covered by the Semi-Annual Financial Report.
  • Dropped Laboratory Good Practice and Clinical Good Practice), whereby the results obtained will represent the scientific value required by the…
  • Dropped Development of the biological veterinary medicinal product BCX-CM-AD intended for the treatment of atopic dermatitis in dogs" ("Project")

Latest announcements

Official filings, newest first.

Similar companies

Healthcare · Biotechnology
All Healthcare companies →